Family offices stepped up their deal-making in April after a slowdown in March triggered by the outbreak of the Iran war, making 55 direct investments in companies last month, up from 39 in March, according to data provided exclusively to CNBC by Fintrx, a private wealth intelligence platform. Nearly a third of April's investments were made in healthcare and life sciences companies, as private wealth moved deeper into the sector while public funding faced cuts and interruptions.
Who Has the Money
Laurene Powell Jobs' Emerson Collective, her investment and philanthropy firm, joined fundraises for two startups: a seed round for Ultralight and a Series A round for Stipple Bio. Ultralight, an artificial intelligence software platform for personalized healthcare, raised $9.3 million in seed funding from Emerson Collective and other investors. Stipple Bio, a developer of targeted cancer therapies, raised $100 million in the round, which was co-led by Andreessen Horowitz. Emerson Collective's investment in Stipple Bio was managed by Yosemite, an oncology-focused venture fund founded by Reed Jobs, Powell Jobs' son with Steve Jobs. The Apple co-founder died in 2011 from complications of pancreatic cancer.
Also in April, Dolby Family Ventures joined a 53 million euro, or $62 million, Series B round for Exciva, a developer of treatments for agitation in Alzheimer's patients. Dolby Family Ventures was founded by David Dolby in 2014, about a year after his father, billionaire engineer Ray Dolby, died of complications of Alzheimer's disease and acute leukemia. The family-office world is not exactly hiding its priorities: capital flows toward the diseases that touch the wealthy, the platforms that promise personalized care, and the venture rounds that can be packaged as both profit and philanthropy.
Who Gets Left Waiting
The influx of private capital comes during cuts and interruptions to federal funding for healthcare research, and a budget proposal released by the Trump administration in April seeks to cut an additional $5 billion from the National Institutes of Health. That is the hierarchy in plain view: public research gets squeezed, while private money steps in to pick the projects it likes, the startups it wants, and the therapies it can own.
In February, a survey released by J.P. Morgan Private Bank found that half of family offices cited healthcare innovation as a top investment theme, second only to artificial intelligence, at 65%. The numbers show where the attention is going. Healthcare is not being treated as a public good to be collectively funded and shared, but as a theme for private portfolios and family wealth strategies.
The April slowdown in March, triggered by the outbreak of the Iran war, briefly interrupted the pace of deal-making. But by April, family offices were back at it, with 55 direct investments in companies. Nearly a third of those investments went into healthcare and life sciences, reinforcing the pattern of private capital moving into sectors where public systems are being starved.
What the Market Calls Care
Ultralight’s $9.3 million seed round, Stipple Bio’s $100 million raise, and Exciva’s 53 million euro Series B all sit inside the same arrangement: wealthy family offices and venture firms deciding which health technologies deserve money while federal support is cut back. Emerson Collective calls itself an investment and philanthropy firm, but the money still moves through fundraises, rounds, and managed investments. Yosemite, the oncology-focused venture fund founded by Reed Jobs, handled Emerson Collective's investment in Stipple Bio.
The result is a healthcare landscape increasingly shaped by private wealth, family offices, and venture capital, even as the public side is told to absorb another round of cuts. The Trump administration’s April budget proposal to cut an additional $5 billion from the National Institutes of Health makes the imbalance even starker. Private capital is not filling a gap so much as moving into the space left open when public funding is pulled back.
The family-office surge in April shows how quickly capital can reorient itself toward healthcare and life sciences when the conditions are right. The people who need research, treatment, and public investment are left in a system where the money is increasingly controlled by firms, funds, and family offices that answer to wealth first.